{"entity":{"id":"raise","kind":"trial","name":"RAISE","aka":[],"tldr":"Switching from one blood-vessel drug to another after progression gave about six extra weeks, the same small gain as aflibercept.","summary":"RAISE randomised 1,072 patients whose metastatic colorectal cancer had progressed during or within six months of first-line bevacizumab, oxaliplatin and a fluoropyrimidine to second-line FOLFIRI with ramucirumab 8 mg/kg or placebo. Median overall survival was 13.3 against 11.7 months. Ramucirumab blocks VEGF receptor 2 rather than the ligand, and the result shows that continued blockade of the pathway after progression helps a little but does not overcome resistance. It is not funded for colorectal cancer in England.","status":"positive","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01183780","url":"https://clinicaltrials.gov/study/NCT01183780"},{"label":"RAISE: ramucirumab with second-line FOLFIRI in metastatic colorectal carcinoma (Lancet Oncology 2015)","url":"https://doi.org/10.1016/S1470-2045(15)70127-0"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":["vegf"],"drugs":["ramucirumab","folfiri"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":["velour"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01183780","phase":"3","setting":"Metastatic colorectal cancer progressing on first-line bevacizumab, oxaliplatin and a fluoropyrimidine: FOLFIRI with ramucirumab or placebo","sponsor":"Eli Lilly","result":"Median overall survival 13.3 against 11.7 months.","yearReported":2015,"enrolled":1072,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"FOLFIRI plus ramucirumab","n":536,"value":13.3},{"name":"FOLFIRI plus placebo","n":536,"value":11.7}],"source":"https://doi.org/10.1016/S1470-2045(15)70127-0"}]},"route":"/trials/raise/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}],"trial":[{"id":"velour","kind":"trial","name":"VELOUR","route":"/trials/velour/"}]}}